Susan Masson

Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial

Chris Parker, Noel W. Clarke, Adrian Cook et al. · The Lancet · 2024 · 49 citations · Full text

Medicine, Oncology, Surgery +15

Final quality of life and safety data for patients with metastatic castration‐resistant prostate cancer treated with cabazitaxel in the <scp>UK</scp> Early Access Programme (EAP) ( <scp>NCT</scp> 01254279)

Amit Bahl, Susan Masson, Zafar Malik et al. · British Journal of Urology · 2015 · 41 citations

Medicine, Oncology, Pharmacology +17

129 Cabazitaxel for metastatic castration resistant prostate cancer (mCRPC): Interim safety and quality of life (QOL) data from the UK early access programme

Amit Bahl, Susan Masson, Zafar Malik et al. · European Urology Supplements · 2012 · 14 citations

Medicine, Oncology, Pharmacology +13

HDR Brachytherapy in the Management of High-Risk Prostate Cancer

Susan Masson, Raj Persad, Amit Bahl · Advances in Urology · 2012 · 12 citations · Full text

Medicine, Oncology, Urology +17

ESICM LIVES 2016: part three

T. Velasquez, J. Lusk, Ursula G. Kyle et al. · Intensive Care Medicine Experimental · 2016 · 12 citations · Full text

Computing, Health Services Administration, Health Systems Leadership +5